To assess the efficacy of probiotic in patients with Irritable Bowel Syndrome

Not Applicable

• Conditions: Health Condition 1: K58- Irritable bowel syndrome

• Registration Number: CTRI/2023/01/049077
• Lead Sponsor: Velbiom Probiotics Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 February 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Diagnosed case of IBS using Rome III criteria

2. Absence of red flag signs: anemia, fever, weight loss, per rectal bleeding, nocturnal frequency, family history of IBD, cancer

3. Age 18-70 years 4. No synthetic probiotics used in prior 3 months

5. No antibiotics used in previous 2 months of enrolment

Exclusion Criteria

1. Previous treatment with probiotics within last 3 months

2. Pregnant or lactating women

3. History of any previous surgical resection of the stomach, small intestine, or large intestine

4. Complications from infectious enteritis, hyperthyroidism, or hypothyroidism.

5. History of any diet-based intolerance (gluten or lactose intolerance).

6. History of or complications from malignant tumors.

7. Uncontrolled Type II diabetes mellitus.

8. Allergic or sensitive to probiotic products.

Study & Design

• Study Type: Interventional
• Study Design: Not specified